Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working
Fiche publication
Date publication
janvier 2017
Journal
Journal of hematology & oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr RUBIO Marie Thérèse , Dr D'AVENI-PINEY Maud
Tous les auteurs :
Rubio MT, D'Aveni-Piney M, Labopin M, Hamladji RM, Sanz MA, Blaise D, Ozdogu H, Daguindeau E, Richard C, Santarone S, Irrera G, Yakoub-Agha I, Yeshurun M, Diez-Martin JL, Mohty M, Savani BN, Nagler A
Lien Pubmed
Résumé
The impact of the use of anti-thymocyte globulin (ATG) in allogeneic stem cell transplantation performed with HLA-identical sibling donors following fludarabine and 4 days intravenous busulfan myeloablative conditioning regimen has been poorly explored.
Mots clés
Adolescent, Adult, Aged, Antilymphocyte Serum, therapeutic use, Busulfan, therapeutic use, Female, Graft vs Host Disease, prevention & control, HLA Antigens, Hematopoietic Stem Cell Transplantation, methods, Histocompatibility, immunology, Humans, Leukemia, Myeloid, Acute, therapy, Leukocyte Reduction Procedures, Lymphocyte Depletion, Male, Middle Aged, Myeloablative Agonists, therapeutic use, Retrospective Studies, T-Lymphocytes, Transplantation Conditioning, methods, Treatment Outcome, Vidarabine, analogs & derivatives, Young Adult
Référence
J Hematol Oncol. 2017 01 24;10(1):31